S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
How major US stock indexes fared Thursday, 3/28/2024
MillerKnoll, Chemours fall; Verint Systems, RH rise, Thursday, 3/28/2024
Mark Zuckerberg Says This CEO Is the 'Taylor Swift of Tech'
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
How major US stock indexes fared Thursday, 3/28/2024
MillerKnoll, Chemours fall; Verint Systems, RH rise, Thursday, 3/28/2024
Mark Zuckerberg Says This CEO Is the 'Taylor Swift of Tech'
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
How major US stock indexes fared Thursday, 3/28/2024
MillerKnoll, Chemours fall; Verint Systems, RH rise, Thursday, 3/28/2024
Mark Zuckerberg Says This CEO Is the 'Taylor Swift of Tech'
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
How major US stock indexes fared Thursday, 3/28/2024
MillerKnoll, Chemours fall; Verint Systems, RH rise, Thursday, 3/28/2024
Mark Zuckerberg Says This CEO Is the 'Taylor Swift of Tech'
NASDAQ:GERN

Geron (GERN) Stock Price, News & Analysis

$3.30
-0.01 (-0.30%)
(As of 03/28/2024 ET)
Today's Range
$3.27
$3.34
50-Day Range
$1.75
$3.44
52-Week Range
$1.64
$3.73
Volume
6.21 million shs
Average Volume
20.37 million shs
Market Capitalization
$1.80 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.33

Geron MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
61.6% Upside
$5.33 Price Target
Short Interest
Bearish
9.33% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-3.23
Upright™ Environmental Score
News Sentiment
0.38mentions of Geron in the last 14 days
Based on 8 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.34) to ($0.14) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.34 out of 5 stars

Medical Sector

351st out of 939 stocks

Pharmaceutical Preparations Industry

166th out of 444 stocks

GERN stock logo

About Geron Stock (NASDAQ:GERN)

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.

GERN Stock Price History

GERN Stock News Headlines

Geron Stock Doubles After Imetelstat Receives FDA Panel Approval
Geron Inc. NASDAQ: GERN is a clinical-stage biotech in the medical sector focused on developing cell therapies to treat certain types of blood cancers and myeloid hematologic malignancies. Their lead drug is imetelstat, which blocks a protein called telomerase to treat specific blood cancers like myelofibrosis and myelodysplastic syndromes.
Geron Stock Doubles After Imetelstat Receives FDA Panel Approval
Geron stock is up more than 92% after the company's flagship blood cancer therapy received approval from an FDA advisory panel
Bombshell 2024 election documentary
2024: America’s Last Election New documentary reveals why this could be America’s Last Election… and how the elites’ plan threatens to reset the entire U.S. economy, along with your 401(k), bank, and stock portfolio.
GERN Mar 2024 3.500 put
Bombshell 2024 election documentary
2024: America’s Last Election New documentary reveals why this could be America’s Last Election… and how the elites’ plan threatens to reset the entire U.S. economy, along with your 401(k), bank, and stock portfolio.
Geron's (GERN) "Outperform" Rating Reaffirmed at Wedbush
GERN Apr 2024 1.000 put
GERN Apr 2024 1.500 call
Geron Corp.
MDGL Apr 2024 270.000 call
Stifel Nicolaus Reaffirms Their Buy Rating on Geron (GERN)
Why Is Geron (GERN) Stock Up 94% Today?
See More Headlines
Receive GERN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Geron and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/28/2024
Today
3/29/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:GERN
CUSIP
37416310
Employees
141
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$5.33
High Stock Price Target
$6.00
Low Stock Price Target
$5.00
Potential Upside/Downside
+61.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-184,130,000.00
Net Margins
-77,691.14%
Pretax Margin
-77,690.72%

Debt

Sales & Book Value

Annual Sales
$240,000.00
Book Value
$0.46 per share

Miscellaneous

Free Float
529,131,000
Market Cap
$1.80 billion
Optionable
Optionable
Beta
0.55
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Dr. John A. Scarlett M.D. (Age 73)
    Chairman of the Board, President & CEO
    Comp: $1.53M
  • Dr. Andrew J. Grethlein Ph.D. (Age 60)
    Executive VP & COO
    Comp: $847.2k
  • Ms. Michelle J. Robertson (Age 56)
    Executive VP, CFO, Treasurer and Principal Financial & Accounting Officer
  • Ms. Aron Feingold
    Vice President of Investor Relations & Corporate Communications
  • Mr. Scott Samuels
    Executive VP, Chief Legal Officer & Corporate Secretary
  • Ms. Shannon Odam (Age 49)
    Senior VP & Chief People Officer
  • Ms. Melissa A. Kelly Behrs (Age 60)
    Executive VP of Business Operations & Chief Alliance Officer
    Comp: $753.22k
  • Mr. Anil Kapur (Age 53)
    Executive VP of Corporate Strategy & Chief Commercial Officer
    Comp: $654.89k
  • Mr. Edward E. Koval (Age 62)
    Executive VP & Chief Business Officer
  • Dr. Faye Feller M.D. (Age 41)
    Executive VP & Chief Medical Officer

GERN Stock Analysis - Frequently Asked Questions

Should I buy or sell Geron stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Geron in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" GERN shares.
View GERN analyst ratings
or view top-rated stocks.

What is Geron's stock price target for 2024?

3 Wall Street analysts have issued 12 month target prices for Geron's shares. Their GERN share price targets range from $5.00 to $6.00. On average, they expect the company's stock price to reach $5.33 in the next year. This suggests a possible upside of 61.6% from the stock's current price.
View analysts price targets for GERN
or view top-rated stocks among Wall Street analysts.

How have GERN shares performed in 2024?

Geron's stock was trading at $2.11 at the start of the year. Since then, GERN shares have increased by 56.4% and is now trading at $3.30.
View the best growth stocks for 2024 here
.

Are investors shorting Geron?

Geron saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 50,950,000 shares, an increase of 13.4% from the February 29th total of 44,910,000 shares. Based on an average daily volume of 10,820,000 shares, the short-interest ratio is currently 4.7 days.
View Geron's Short Interest
.

When is Geron's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our GERN earnings forecast
.

How were Geron's earnings last quarter?

Geron Co. (NASDAQ:GERN) posted its earnings results on Wednesday, February, 28th. The biopharmaceutical company reported ($0.09) earnings per share for the quarter, beating the consensus estimate of ($0.10) by $0.01. The biopharmaceutical company earned $0.02 million during the quarter, compared to analysts' expectations of $0.06 million. Geron had a negative net margin of 77,691.14% and a negative trailing twelve-month return on equity of 63.33%. The company's quarterly revenue was down 77.7% on a year-over-year basis. During the same quarter last year, the business earned ($0.10) EPS.

What ETFs hold Geron's stock?
What is John A. Scarlett's approval rating as Geron's CEO?

5 employees have rated Geron Chief Executive Officer John A. Scarlett on Glassdoor.com. John A. Scarlett has an approval rating of 82% among the company's employees.

What other stocks do shareholders of Geron own?
Who are Geron's major shareholders?

Geron's stock is owned by many different retail and institutional investors. Top institutional investors include Vanguard Group Inc. (5.26%), Vanguard Group Inc. (5.23%), Vivo Capital LLC (4.45%), Wellington Management Group LLP (1.74%), Northern Trust Corp (0.94%) and Charles Schwab Investment Management Inc. (0.71%). Insiders that own company stock include Andrew J Grethlein, Elizabeth G O'farrell, John A Scarlett, Olivia Kyusuk Bloom, Susan Molineaux and V Bryan Lawlis.
View institutional ownership trends
.

How do I buy shares of Geron?

Shares of GERN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:GERN) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners